It is financial reporting season, and a few major medtech companies posted third-quarter sales growth. | It is financial ...

Sherlock Biosciences has teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech for new tests on the latter’s automated laboratory systems. The collaboration will focus on ...

Cepheid is developing a rapid test, known as Xpert Carba-R, for detecting multidrug-resistant pathogens. The test has several advantages over existing diagnostic methods. The company successfully ...

Q3 2025 Management View CEO Rainer Blair emphasized strong third quarter results, driven by "DBS-driven execution paired with ...

Shares in biotechnology, life sciences, and diagnostics company Danaher (NYSE: DHR) rose by as much as 12.9% in early morning ...

PARIS & CAMBRIDGE, England--(BUSINESS WIRE)--Regulatory News: Novacyt (ALTERNEXT: ALNOV), an international specialist in clinical diagnostics, today announces it has entered into a strategic alliance ...

Danaher stock surged over 7% on Tuesday after the company delivered a solid third-quarter performance, with revenues rising 4 ...

(RTTNews) - Cepheid, a unit of Danaher Corp. (DHR), said Thursday that it has received a medical device license from Health Canada for Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic ...

The all-cash deal will expand Danaher's already hefty life sciences division. D.C.-based Danaher Corp. (NYSE: DHR) is buying California molecular diagnostics company Cepheid Inc. (NASDAQ: CPHD) for ...

(Reuters) - Molecular diagnostics company Cepheid said it received a grant of up to $3.3 million, co-financed by the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation, to develop ...

For much of last year, the coronavirus crept, undetected, across eastern Democratic Republic of Congo. Test samples had to be sent more than 1,500 kilometres from remote hospitals to the capital ...